First Round is a seed-stage venture firm focused on building a vibrant community of technology entrepreneurs and companies, including Uber, Square, and Warby Parker. Through custom-built software, incredible in-person experiences, and a host of other unique services, First Round helps tiny companies get big while constantly reimagining the role of venture capital. It offers a growing number of services and products to help founders build companies from scratch. First Round has adopted the Diversity Term Sheet Rider.

First Round Capital

Felicis Ventures is a venture capital firm based in Menlo Park, California. The firm invests in seed through Series C stage companies across multiple sectors and industries reinventing core markets, as well as those creating frontier technologies. Felicis currently manages over $2B in capital across 8 funds. The firm is an early backer of more than 40 companies valued at $1B+. More than 90 of its portfolio companies have been acquired or gone public since the firm was founded by Aydin Senkut in 2006.

Felicis

Uncork Capital is a seed-stage venture capital firm that focuses on SaaS, consumer, marketplaces, hardware, and new technology startups. The firm currently investing out of two funds: a $200M Seed fund (Fund VII) and a $200M Opportunity fund (Plus III) earmarked for larger investments in mature, existing portfolio companies. Uncork Capital, formerly SoftTech VC was founded in 2004 and is based in Palo Alto, California, United States. Uncork Capital has adopted the Diversity Term Sheet Rider.

Uncork Capital

SV Angel is a San Francisco-based venture fund. Their experience spans helping companies like Airbnb, Coinbase, Databricks, DoorDash, Faire, Flexport, GitHub, Notion, Pinterest, Snap, Square, and Stripe Scale. Over the last 30 years of investing, their core values of trust, loyalty, and integrity along with a founder-first approach have driven our strategy. They are a service organization, investing in founders who share these values. They support entrepreneurs in building lasting companies by assisting at key inflection points and leveraging networks to help them propel their businesses forward.

SV Angel

Funding and support for concept and seed stage startups.  K9 Ventures is a true early stage venture fund that provides funding and support for concept-stage and seed-stage technology companies. We work with entrepreneurs, sometimes even before a company has been formed, to help evaluate, evolve and fund a company in its nascent stages. K9 Ventures focuses on startups in the San Francisco Bay Area that have a strong entrepreneur/team, an idea that has a clear path to revenue, which can be capital efficient and where they can add value.

K9 Ventures

GV supports innovative founders moving the world forward. We invest across the life sciences, consumer, enterprise, crypto, climate, and frontier technology sectors. With Alphabet as a sole limited partner, GV operates on long time horizons and deals in decades, not rounds. Our operating partners support startups at the earliest stages of company-building across design, equity, diversity & inclusion, talent, and engineering. We also help startups interface with Google, providing unique access to the world's best technology and talent. Launched as Google Ventures in 2009, GV has over $8 billion in assets under management and 400 active portfolio companies across North America and Europe. Notable investment outcomes include Uber, Nest, Slack, GitLab, Duo Security, Flatiron Health, Verve Therapeutics, and One Medical. GV is headquartered in the San Francisco Bay Area, with offices in Cambridge, New York, and London.

Google Ventures

TPG Biotech is part of the growth equity and venture investment platform of TPG, the global private investment firm.  TPG Biotech targets investments in pharmaceutical discovery and development, medical technology, diagnostics, healthcare and pharmaceutical services, life sciences, as well as industrial applications of biotechnology.  TPG Biotech has access to the broader resources of TPG.

TPG Biotech

Claremont Creek Ventures (CCV) is a seed and early stage venture firm. CCV invests in companies that serve essential, broad-impact industries with innovative digital solutions that increase efficiency or create entirely new high-growth, high-margin businesses. As part of CCV’s investment strategy, the firm practices “life cycle venturing”: establishing in-depth, active relationships with entrepreneurs alongside or even ahead of early-stage funding events. Claremont Creek Ventures has invested in over 40 companies including Clean Power Finance, EcoATM, and Natera and manages more than $300 million across two funds. Visit www.claremontcreek.com.

Claremont Creek Ventures

WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient solutions,With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec's open-access platform is enabling more than 3,900 collaborators from over 30 countries to improve the health of those in need – and to realize our vision that ''every drug can be made and every disease can be treated''.

WuXi AppTec

Foresite Capital is a healthcare and life sciences investment firm. They take a data-driven approach to invest in startups that employ biology and big data to improve healthcare, such as 10x Genomics, Relay Therapeutics, Element Biosciences, and Inscripta.

Foresite Capital

MidCap Financial is a middle market-focused, specialty finance firm that provides senior debt solutions to companies across all industries. We provide a broad array of products intended to finance growth and manage working capital.  As of January 2015, MidCap Financial has over $3 billion of commitments under management. Since our founding in 2008, we have been working with management teams and sponsors to deliver thoughtful and cost effective debt solutions. Companies need a lender that understands their business and has the creativity and flexibility to provide financing solutions that are suited to their needs. At MidCap Financial, our years of experience, strong balance sheet, and flexibility make us the lender of choice for companies across all stages of growth and complexity.  MidCap Financial is managed by Apollo Capital Management, L.P., a subsidiary of Apollo Global Management, LLC, pursuant to an investment management agreement. Apollo Global Management is one of the world's largest asset managers with over $160B of assets under management (as of January 2015), providing market leading industry expertise, market reach, and financing synergies.

MidCap Financial

Microsoft is an American multinational corporation that develops, manufactures, licenses, supports, and sells a range of software products and services. Microsoft’s devices and consumer (D&C) licensing segment licenses the Windows operating system and related software, Microsoft Office for consumers, and the Windows Phone operating system. The company’s computing and gaming hardware segment provides Xbox gaming and entertainment consoles and accessories, second-party and third-party video games, and Xbox Live subscriptions; surface devices and accessories; and Microsoft PC accessories. Its phone hardware segment offers Lumia smartphones and other non-Lumia phones. Its D&C segment provides Windows Store, Xbox Live transactions, and Windows phone store; search advertising; display advertising; Office 365 Home and Office 365 Personal; first-party video games; and other consumer products and services as well as operating retail stores. Microsoft’s commercial licensing segments license server products, including Windows Server, Microsoft SQL Server, Visual Studio, System Center, and related Client Access Licenses (CALs); Windows Embedded; Windows operating system; Microsoft Office for business, including Office, Exchange, SharePoint, Lync, and related CALs; Microsoft Dynamics business solutions; and Skype. Its commercial segment offers enterprise services, including premier support services and Microsoft consulting services; commercial cloud comprising Office 365 Commercial, other Microsoft Office online offerings, Dynamics CRM Online, and Microsoft Azure; and other commercial products and online services. The company markets and distributes its products through original equipment manufacturers, distributors, and resellers, as well as online.

Microsoft

Genuity Science provides clinco-omics data analysis solutions for researchers. They also provide genomic sequence data. Their platform offers study design, sequencing, storage, interpretation, secondary analysis, and scalable analytics, enabling organizations to improve patient health using the human genome.

Genuity Science

Innovatus Capital Partners, they focus on both real and financial assets. Their firm's investment in strategies that identifies distressed, disruptive, and growth opportunities.

Innovatus Capital Partners

Perceptive Advisors is a privately owned hedge fund sponsor. The firm invests in the public equity markets across the globe. It employs a long/short equity strategy as a hedging technique while investing. The firm typically invests in the biotechnology and life sciences sectors to make its investments. Perceptive Advisors is based in New York, New York.

Perceptive Advisors

Northpond Ventures is a science-driven venture capital ﬁrm headquartered in Bethesda, Maryland. Our mission is to build a better tomorrow.  Our investments are focused on life sciences, technology, and aﬃliated industries.

Northpond Ventures

Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders.   The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%.    Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.

Regeneron

Blackstone Accelerates Growth (BxG) creates jobs and economic development through entrepreneurship and growth. They work with their partners to create statewide programs with coordinated, focused activities to accelerate companies, connections, and the next generation of Maine entrepreneurs. They operate as part of the Blackstone Charitable Foundation, a $50 million Entrepreneurship Initiative to support innovative programs that drive job creation.

Blackstone Accelerates Growth

DNAnexus

DNAnexus develops a cloud platform and global network designed for scientific collaboration and accelerated discovery. It provides security, scalability, and collaboration for enterprises and organizations that are pursuing genomic-based approaches to health in order to accelerate medical discovery. DNAnexus is supporting customers around the world that are tackling some of the most challenging and exciting opportunities in human health. The company was founded in 2009 and is based in Mountain View, California.

<div>DNAnexus operates a cloud-based platform for genomic research. The platform, named DNAnexus Precision Health Data Platform, manages and analyzes precision health data, integrating multiomics with clinical data. It features bioinformatics tools, JupyterLab notebooks, and visualization applications, facilitating omics and phenotypic data management, workflow automation, and collaborative scientific research within a secure and compliant environment.</div>

Artificial intelligence is identifying and testing new therapies faster than ever.

AI Drug Discovery

<div>DNAnexus is a multiomics startup that operates a cloud-based data analysis platform offering insights from genomic, multiomics (transcriptomic, proteomic, and metabolomic), and clinical datasets to pharma and biotech companies for precision medicine discovery. Additionally, its platform is used by diagnostic test providers, sequencing service providers, academic labs, and genome centers. DNAnexus has three products: 1) Apollo, to support data science exploration, analysis, and discovery, 2) Titan, for sequencing data analysis, and 3) Portals, a collaborative space for organizations.</div>

Leveraging personal data for custom-fit diagnosis and treatment

Precision Medicine

DNAnexus and Galatea Bio Launch Collaboration to Enhance Precision Medicine with Advanced Genetic Tools for Underserved Populations

<div>
 
 DNAnexus operates a cloud-based platform for genomic research. The platform, named DNAnexus Precision Health Data Platform, manages and analyzes precision health data, integrating multiomics with clinical data. It features bioinformatics tools, JupyterLab notebooks, and visualization applications, facilitating omics and phenotypic data management, workflow automation, and collaborative scientific research within a secure and compliant environment.
 
 
 Key customers and partnerships
 
 
 DNAnexus&rsquo; platform is used by a diverse set of entities including pharmaceutical and biotech companies, diagnostic test providers, sequencing service providers, academic labs, and genome centers. As of March 2024, DNAnexus had more than 45,000 platform users across 48 countries. The company offers its platform to more than 130 enterprise customers including eight large clinical diagnostic companies and seven big pharma companies.
 
 
 The company established several key partnerships, including partnerships with 1) the FDA, to develop a platform that tests the accuracy of diagnostic genetic tests (
 <a href="https://www.businesswire.com/news/home/20150805006334/en/DNAnexus-to-Deliver-precisionFDA">
 August 2015)
 </a>
 , 2) AstraZeneca, to analyze over 2 million genomes through 2027 (
 <a href="https://www.businesswire.com/news/home/20170523005582/en/DNAnexus-to-Partner-With-AstraZeneca%E2%80%99s-Centre-for-Genomics-Research">
 May 2017
 </a>
 ), 3) Regeneron Genetics Center, to leverage DNAnexus's interface to query data from the UK Biobank, an academic-run database of genomic and clinical data (
 <a href="https://www.dnanexus.com/press/innovative-cloud-based-research-analysis-platform-launched-to-increase-scale-and-accessibility-of-resource">
 September 2021
 </a>
 ), and 4) Intelliseq, to accelerate genome interpretation and clinical reporting (
 <a href="https://sp-edge.com/updates/25471">
 January 2024
 </a>
 ).&nbsp;
 
 
 Funding and financials
 
 
 In 
 <a href="https://sp-edge.com/updates/8979">
 March 2022
 </a>
 , DNAnexus raised USD 200 million in a Series H funding round led by Blackstone Growth. The round valued the company at USD 600 million. The funds raised were to advance its core genomics and multiomics platform. The company planned to enhance its AI and machine learning capabilities and accelerate the global commercial deployment of its platform.
 
</div>

<div>
 
 e-Therapeutics is a UK-based company specializing in drug discovery and development. It leverages computational biology to expedite the drug discovery process, particularly in RNA interference (RNAi) medicines. The company's approach integrates network analysis, machine learning, AI, data mining, and optimization into its proprietary databases and computational tools to identify and develop therapies.&nbsp;
 
 
 The company utilizes two platforms: 1) The HepNet Computational Platform, which is an in-silico (performed via computer simulation) laboratory that allows users to conduct hypotheses, phenotypic screening, and the identification and prioritization of novel therapeutic targets, and 2) the GalOmic RNAi Platform that enables highly specific silencing of gene expression and specializes in the development of RNAi therapies.
 
 
 Further, it has four drug candidates in the pipeline, namely 1) ETX-312 to treat metabolic dysfunction-associated steatohepatitis (MASH), 2) ETX-407 to treat dry age-related macular degeneration (dAMD), 3) ETX-148 to treat pan-haemophilia, and 4) ETX-291 to treat a broad spectrum of cardiometabolic diseases.
 
 
 Key customers and partnerships
 
 
 The company&rsquo;s customers include several pharmaceutical companies to develop therapies using its proprietary platforms. These include partnerships with 
 <a href="https://www.etherapeutics.co.uk/news-and-media/press-releases/e-therapeutics-signs-research-collaboration-agreement-novo-nordisk/">
 Novo Nordisk
 </a>
 (December 2018), 
 <a href="https://www.etherapeutics.co.uk/news-and-media/press-releases/collaboration-galapagos-discover-new-therapeutic-strategies-treatment-idiopathic-pulmonary-fibrosis-and-other-fibrotic-condition/">
 Galapagos
 </a>
 (June 2020), and 
 <a href="https://www.etherapeutics.co.uk/news-and-media/press-releases/immuno-oncology-research-collaboration-iteos-therapeutics/">
 iTeos Therapeutics 
 </a>
 (April 2022). It is also working with another undisclosed top-five pharma company in a specific area of neurodegeneration.&nbsp;
 
 
 Further in May 2018, the company partnered with C4X Discovery to identify new pathophysiological mechanisms in Parkinson&rsquo;s disease.&nbsp;
 
 
 Funding and financials
 
 
 In 2007, the company was listed on the Alternative Investment Market, the London Stock Exchange&rsquo;s public market for small and medium-sized growth companies, under the ticker symbol &ldquo;ETX&rdquo;. Further in 
 <a href="https://sp-edge.com/updates/13462">
 September 2022
 </a>
 , the company raised GBP 13.5 million (USD 15.1 million) from funds managed by institutional investor M&amp;G Investment Management Limited via the subscription of new ordinary shares. The funds were expected to be used for the company's growth initiatives.
 
</div>

eTherapeutics

<div>
 
 HiberCell is a biotechnology company that develops novel therapies focused on oncology. It entered the AI drug discovery space when it acquired AI genomics analysis company Genuity Science (and its subsidiaries in Iceland and Ireland) in August 2021.&nbsp;
 
 
 Genuity Science&rsquo;s solutions include end-to-end therapeutic discovery and development services such as building custom disease datasets, discovering and prioritizing targets, identifying biomarkers, and optimizing clinical trials. Genuity Science leverages its AI-powered platform to manage, process, and analyze genomic data. HiberCell intends to use Genuity Science&rsquo;s AI/ML capabilities to advance its oncology pipeline of five programs, of which one has reached the Phase 2 clinical trial stage.
 
 
 As of March 2024, the company&rsquo;s pipeline included three drug candidates, namely: 1) HC-7366, targeting the general control nonderepressible 2 (GCN2) kinase as part of the integrated stress response (ISR) signaling pathway; 2) HC-5404, aimed at inhibiting the PKR-like endoplasmic reticulum kinase (PERK) involved in the unfolded protein response (UPR) signaling pathway; and 3) odetiglucan, a therapy targeting tumor-immune interactions within the tumor microenvironment​.&nbsp;
 
 
 Key customers and partnerships
 
 
 In December 2023, HiberCell and Merck &amp; Co partnered to conduct a Phase Ib trial to evaluate the combination therapy of belzutifan and HC-7366 for treating clear cell renal cell carcinoma. Further, in January 2021, the company partnered with Biodesix to develop an enzyme-linked immunosorbent assay as a companion diagnostic test.
 
 
 Funding and financials
 
 
 In 
 <a href="https://hibercell.com/news/hibercell-closes-67-4-million-series-b-financing-and-secures-30-million-debt-facility-from-hercules-capital/">
 May 2021
 </a>
 , HiberCell completed a Series B financing round, raising USD 67.4 million, and secured an additional USD 30 million in debt financing from Hercules Capital. The funds were expected to be used for clinical advancement of its novel therapeutic candidates. 
 
</div>

HiberCell

<div>
 
 Arbor Biotechnologies specializes in gene editing to develop novel therapeutics for a variety of indications, starting with liver-related diseases. It operates an AI-powered biodiscovery platform to discover novel CRISPR enzymes, which are sequences of repeating genetic code. To do this, its platform deploys computational search techniques, genome sequencing, gene synthesis, and high-throughput screening. This can eventually be turned into drugs or even applied to agriculture and other industrial uses. In 2018, the company announced the discovery of Cas13d, a new type of gene editing enzyme that helps to alter RNA to treat genetic diseases.&nbsp;
 
 
 As of February 2024, the company had five internal drug discovery programs, of which one was in the IND-enabling stage. It also has multiple collaborative programs under development focused on oncology and various other therapeutic areas.
 
 
 Key customers and partnerships
 
 
 The company has a long-standing partnership with Vertex Pharmaceuticals since
 <a href="https://www.businesswire.com/news/home/20190103005194/en/Vertex-and-Arbor-Biotechnologies-Establish-Collaboration-to-Discover-Novel-Proteins-to-Advance-Discovery-of-Gene-Editing-Therapies">
 January 2019
 </a>
 , which focused on developing gene-editing treatments for cystic fibrosis and four other diseases. The alliance was further extended in 
 <a href="https://www.biospace.com/article/vertex-and-arbor-strike-a-1-2-billion-deal-for-gene-editing-programs/">
 August 2021
 </a>
 and 
 <a href="https://sp-edge.com/updates/15741">
 January 2023
 </a>
 .&nbsp;
 
 
 Other partnerships included a collaboration with 
 <a href="https://www.prnewswire.com/news-releases/arbor-biotechnologies-announces-collaboration-with-ginkgo-bioworks-to-advance-the-discovery-and-development-of-precision-gene-editors-302011991.html">
 Ginkgo Bioworks
 </a>
 (December 2023) to leverage Ginkgo's R&amp;D services to further optimize Arbor's novel precision editors, a non-exclusive licensing agreement with 
 <a href="https://www.globenewswire.com/news-release/2022/02/08/2380680/0/en/EdiGene-and-Arbor-Biotechnologies-Announce-Worldwide-Non-exclusive-License-Agreement-to-Advance-Ex-Vivo-Engineered-Cell-Therapy-Programs.html">
 EdiGene
 </a>
 (February 2022) to leverage Arbor&rsquo;s platform for ex vivo oncology therapies, a strategic research and non-exclusive licensing agreement with 
 <a href="https://investors.tcr2.com/news-releases/news-release-details/tcr2-therapeutics-and-arbor-biotechnologies-establish">
 TCR2 Therapeutics
 </a>
 (January 2022) to develop allogeneic TRuC T-cell therapies using Arbor&rsquo;s CRISPR technology, and a license agreement with 
 <a href="https://www.lonza.com/news/2020-12-23-14-00">
 Lonza
 </a>
 (December 2020) to use Arbor&rsquo;s gene-editing technology for Lonza&rsquo;s bioproduction products and services.
 
 
 Funding and financials
 
 
 In its latest Series B funding round in November 2021, which was led by Ally Bridge Group, TCG Crossover, and Temasek, Arbor Biotechnologies raised USD 215 million. The proceeds of the round were earmarked to fuel the company&rsquo;s clinical development pipeline.
 
</div>

Arbor Biotechnologies

Based in the UK, Arctoris provides an automated drug discovery platform, offering fully validated research and development (R&amp;D) processes under an Experiments-as-a-Service model. The company works with biotechnology companies, AI drug discovery companies, pharma and academic institutions enabling these institutions to run experiments in Arctoris’s platform and provides on-demand access to a broad scale of datasets for AI drug discovery companies to train their algorithms.

Arctoris

<div>
 
 Frontier Medicines leverages AI/ML technologies to develop treatments for cancer-causing proteins that are dismissed by traditional pharma companies as undruggable.&nbsp;
 
 
 The company has a proprietary chemoproteomic platform which entails an approach based on the interaction of small-molecule compounds and proteins to screen a large number of targets and combine them with a protein database that contains more than 150,000 novel binding pockets (hotspots). This enables it to access 90% of the human proteome that were not previously targeted due to lack of hotspots. The platform&rsquo;s AI/ML engine incorporates a library of diverse compounds, a hotspot map that serves as the starting point for understanding the druggability of a potential therapeutic target, and lead design and generation.&nbsp;
 
 
 The company focuses on oncology and immunology target and, as of February 2024, it had five wholly-owned therapeutic programs and three AbbVie-partnered programs in its pipeline. All programs were in their discovery stage, except the company&rsquo;s lead candidate, FMC-376 (activated and inactivated forms), focused on treating different cancer types, including non-small cell lung cancer (NSCLC), colorectal carcinoma (CRC), and pancreatic ductal adenocarcinoma (PDAC), which is in the IND-enabling stage.
 
 
 Key customers and partnerships
 
 
 The company entered a USD 100 million partnership with 
 <a href="https://news.abbvie.com/2020-12-02-AbbVie-and-Frontier-Medicines-Establish-Global-Partnership-to-Discover-and-Develop-Novel-Therapies-and-E3-Degraders-Against-Difficult-to-Drug-Targets">
 AbbVie
 </a>
 In December 2020 to develop small-molecule therapeutics against hard-to-drug protein targets including around 600 E3 ligases (the enzymes that drive the ubiquitination and degradation of proteins.&nbsp;
 
 
 Funding and financials
 
 
 In July 2021, the company raised USD 88.5 million in a 
 <a href="https://sp-edge.com/updates/4347">
 Series B
 </a>
 funding round co-led by Woodline Partners LP and RA Capital Management, with equal participation from Deerfield Management Company. The proceeds were earmarked for advancing the company&rsquo;s drug pipeline and expanding operations in Boston, where its new facility was to complement the company&rsquo;s headquarters in California. 
 
</div>

Frontier Medicines

SaaS (Software-as-a-Service) companies providing their ML platform to other pharma companies for drug discovery services such as target selection, validation and lead optimization.

SaaS (Software-as-a-Service) companies providing their ML platform to other pharma companies to design and run preclinical experiments.

SaaS (Software-as-a-Service) companies providing their ML platform to other pharma companies to identify biomarkers (measurable biological signs used to determine disease progression) and predict drug response. 

SaaS (Software-as-a-Service) companies aggregating and analyzing biomedical data with the help of AI to generate insights across the drug development pipeline.

Biotechnology companies that have integrated AI as a core component of their in-house drug development process. They typically have a few in-house drug development programs, and also collaborate with pharma companies to develop certain drugs.

Companies leverage GenAI to support drug discovery through accelerated drug designing

Companies offer AI/ML-based SaaS products to accelerate the discovery and development of novel therapeutics

Offers AI/ML-based solutions to accelerate drug discovery and development

<div>
 
 DNAnexus is a multiomics startup that operates a cloud-based data analysis platform offering insights from genomic, multiomics (transcriptomic, proteomic, and metabolomic), and clinical datasets to pharma and biotech companies for precision medicine discovery. Additionally, its platform is used by diagnostic test providers, sequencing service providers, academic labs, and genome centers. DNAnexus has three products: 1) Apollo, to support data science exploration, analysis, and discovery, 2) Titan, for sequencing data analysis, and 3) Portals, a collaborative space for organizations.
 
 
 Key customers and partnerships
 
 
 As of March 2022, DNAnexus had more than 12,000 platform users across 48 countries. It also built and continues to facilitate the UK Biobank Research Analysis Platform, granting researchers access to this biomedical database and tools from across the world. Additionally, the firm has an exclusive partnership with the FDA to support a cloud-based platform, precisionFDA, which provides data and tools in a collaborative space to support the use of multiomics data in FDA submissions.&nbsp;
 
 
 In January 2024, DNAnexus partnered with genome informatics firm Intelliseq to enhance variant interpretation and clinical reporting. The partnership was expected to add ntelliseq&rsquo;s genome interpretation and reporting services to DNAnexus's Precision Health Data Cloud to enhance next-generation sequencing data analysis. The solution was expected to provide important insights into various fields of biomedicine, including the study of somatic cancers, hereditary diseases, and precision medicine.
 
 
 Funding and Financials
 
 
 The company received its most recent injection of investment in March 2022, when it raised USD 200 million in a Series H funding round led by Blackstone Growth. The round valued the company at USD 600 million and the funds raised were directed toward advancing its core genomics and multiomics platform. The company planned to enhance its AI and machine learning capabilities and accelerate the global commercial deployment of its platform.
 
</div>

<div>
 
 Praxis Precision Medicines is a clinical-stage biopharmaceutical company that develops precision medicine for central nervous system disorders based on neuronal imbalance caused by genetic mutations.
 
 
 The company has four clinical-stage product candidates in its pipeline for treating disorders such as depression, epilepsy, movement disorders, and pain syndromes. The company&rsquo;s drug candidates include 1) PRAX-944, which is an inhibitor for essential tremor disorder linked to Parkinson&rsquo;s disease and is set to begin Phase 3 in mid-2023, 2) PRAX-222 in Phase 2 of clinical trials targets the SCN2A gene most commonly associated with early-onset epilepsy, 3) PRAX-562 was designed to block persistent sodium for patients suffering from rare diseases such as headache disorders and severe seizures and completed Phase 1 of clinical trials, and 4) PRAX-628 in Phase 2 clinical trials for treating focal epilepsy that originates in one side or area of the brain and affects one side of the body. Additionally, the firm has six pre-clinical drug candidates.
 
 
 Funding and financials
 
 
 The company went public in October 2020, trading on the Nasdaq Global Select Market under the ticker symbol &ldquo;PRAX&rdquo;. 
 <a href="https://sp-edge.com/updates/19453">
 In June 2023 
 </a>
 , the company announced an underwritten public offering of its common shares and pre-funded warrants, to raise approximately USD 59.1 million. The capital raised was used to support the company&rsquo;s ongoing operations and strategic initiatives, furthering the development of its pipeline and potential future endeavors.
 
 
 For the year 
 <a href="https://sp-edge.com/updates/16211">
 2022
 </a>
 , net losses increased by 28% YoY to USD 214 million arising from a significant increase in R&amp;D expense (up by 29% YoY). For the six months ended June 2023, the company is yet to generate revenue from drugs, however received collaboration revenue of USD 1.5 million. Further, it reported a decline in net loss by 43.0% YoY to USD 34.3 million. Its cash and cash equivalent as of June 2023 was at USD 124.3 million, compared to USD 61.6 million in December 2022, which the company believes will be adequate to fund operations till Q1 2025. 
 
</div>

Praxis Precision Medicines

<div>
 
 Mirati Therapeutics is a commercial-stage biotechnology company developing oncology-targeted therapies to address KRAS mutations present in 25% of tumors, including lung, colorectal and pancreatic cancers. Mirati&rsquo;s lead product KRAZATI (adagrasib/ MRTX849) is an oral&nbsp; KRASG12C inhibitor approved in 2022 for certain non-small cell lung cancers.The company also has sitravatinib, a multi-kinase inhibitor, in Phase 3 trials for non-small cell lung cancer in combination with a Bristol-Myers Squibb checkpoint inhibitor.
 
 
 
 
 Additionally, Mirati is advancing multiple early-stage programs including KRAS G12D inhibitor MRTX1133 for pancreatic and colorectal cancers, which entered Phase 1 in 2023, as well as a synthetic lethal inhibitor MRTX1719. In December 2022, the company submitted an IND application for MRTX1133, a potent and selective KRAS G12D inhibitor, which was cleared by the FDA in January 2023. 
 
 
 Key partnerships and customers
 
 
 
 
 Mirati has multiple partnerships with leading biopharma companies to advance its pipeline, including discovery collaborations with Pfizer and clinical collaborations with Novartis, Boehringer Ingelheim, and 
 <a href="https://sp-edge.com/updates/14345">
 Incyte
 </a>
 . The company also has licensing agreements with BeiGene for sitravatinib and Zai Lab for MRTX849 in certain Asian markets.
 
 
 
 
 
 Funding and Financials
 
 
 
 
 The company went public in June 2013 to trade on Nasdaq under the ticker symbol &ldquo;MRTX&rdquo;. In August 2023, the company closed an 
 <a href="https://sp-edge.com/updates/20988">
 underwritten public offering
 </a>
 at USD 345 million. The new funds were used towards drug development and leadership expansion.&nbsp;
 
 
 
 
 <a href="https://sp-edge.com/updates/16725">
 For the year 2022 
 </a>
 , the firm's net losses increased to USD 740.9 million from USD 581.8 million. Net product revenue for the full year amounted to USD 0.7 million arising from the sale of KRAZATI, which received FDA approval for its commercial launch in December 2022. 
 
</div>

Mirati Therapeutics

<div>
 
 Tvardi Therapeutics is a clinical-stage biotechnology company developing precision medicine for different cancers, chronic inflammatory diseases, and fibrotic diseases. The company&rsquo;s pipeline focuses on the development of small-molecule inhibitors of STAT3, a regulatory protein that allows cancer cells to evade the immune system and survive.
 
 
 The company&rsquo;s orally administered monotherapy and lead product, TTI-101, is in Phase 1 clinical trials for patients with advanced solid tumors who have failed all other lines of therapy. Additionally, the drug is in preclinical trials for treating fibrosis and inflammation. The company is also developing TTI-102, a next-generation STAT3 inhibitor that is structurally similar but chemically different from TTI-101.&nbsp;
 
 
 Founded in 2017, the Texas-based company closed a Series B funding round in June 2021, which brought total funding to USD 81 million and the proceeds will be used to advance Tvardi&rsquo;s drug candidates through its clinical data readouts in mid-stage trials for cancer and fibrosis.
 
</div>

Tvardi Therapeutics

<div>
 
 Tango Therapeutics is a clinical-stage biotech company developing precision oncology therapies targeting synthetic lethality in cancer which leads to cell death. Its discovery platform identifies novel targets to develop drugs focused on: 1) countering tumor suppressor gene loss to help the immune system recognize and kill cancer cells, and 2) reversing cancer cell evasion of the immune system.
 
 
 
 
 Tango has five pipeline programs, including lead candidate TNG908, an inhibitor for multiple cancer indicators. The FDA approved TNG908's IND in January 2022 and granted it Orphan Drug Designation. TNG908 is in Phase I/II trials, with preliminary efficacy data expected in H1 2023. Tango also plans to file INDs for TNG260 (STK11 mutant cancers) and TNG348 (BRCA1/2-mutant cancers). In 
 <a href="https://www.globenewswire.com/news-release/2023/01/25/2595034/0/en/Tango-Therapeutics-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-TNG462-Provides-Additional-Business-Updates.html">
 January 2023
 </a>
 , the FDA cleared the IND for TNG462, a next-gen PRMT5 inhibitor for cancers with MTAP deletion.
 
 
 
 
 Key partnerships and customers
 
 
 
 
 
 Outside its pipeline, the company also entered into a collaborative partnership with big pharma Gilead Sciences Inc., in October 2018 which was later expanded for two years in August 2020 to identify new immune evasion targets.
 
 
 
 
 Funding and financials&nbsp;
 
 
 
 
 
 Tango went public in August 2021 via a SPAC deal, trading on Nasdaq under the ticker symbol &ldquo;TNGX&rdquo;, and the company received gross proceeds of USD 353 million. In August 2023, the company raised USD 80 million via a 
 <a href="https://sp-edge.com/updates/20955">
 private placement
 </a>
 , which was led by Nextech. The new funds were used toward expanding its TNG908 and TNG462 PRMT5 programs to various other indications.
 
 
 
 
 Tango has not yet generated any drug sales and does not expect to do so for several years. However, for the full-year the company reported collaboration revenue of USD 24.9 million (down 4.42% YoY) and a net loss of USD 108.2 million (up 85.9% YoY).
 
 
 
</div>

Tango Therapeutics

<div>
 
 IDEAYA Biosciences is a clinical-stage biotech developing precision cancer therapies based on synthetic lethality - when specific gene mutations pair to cause cell death. The company also studies combining synthetic lethality with immunotherapies and DNA damage to enhance treatment efficacy. While current drugs target limited mutations like BRCA1/2, IDEAYA aims to treat broader genetic subpopulations.&nbsp;
 
 
 
 
 Its pipeline includes synthetic lethality-driven precision medicines across four potential first-in-class clinical-stage product candidates. Of these, the company owns/controls commercial rights of the three most-advanced of these product candidates: darovasertib, IDE397, and IDE161. As of May 2024, the company was also advancing Werner Helicase program for which a development candidate has been selected in collaboration with GlaxoSmithKline, and, subject to investigational new drug-, or IND-, enabling studies, are targeting an IND in 2024. In addition. the company also works on multiple earlier-stage preclinical programs. 
 
 
 By targeting specific genetic drivers, IDEAYA advances precision oncology using synthetic lethality approaches. The company is focused on developing novel targeted therapies for patient populations with high unmet need and limited treatment options.&nbsp;&nbsp;
 
 
 In December 2023, IDEAYA Biosciences teamed up with Gilead Sciences to test the combination of IDE397 and Trodelvy in a Phase I clinical trial for MTAP-deletion bladder cancer.
 
 
 
 
 Key partnerships and customers
 
 
 
 
 The company collaborates with pharmaceutical partners to advance its pipeline, including a strategic partnership with GSK in June 2020. The collaboration with GSK covers co-development and commercialization of two synthetic lethality programs. IDEAYA received USD 100 million upfront and USD 20 million in a direct private placement through the GSK deal. In June 2022, IDEAYA announced it would co-develop its Pol Theta candidate with GSK, with a Phase 1 trial starting in the first half of 2023.&nbsp;
 
 
 
 
 IDEAYA also holds an exclusive license from Novartis for LXS196 (IDE196), a PKC inhibitor for metastatic uveal melanoma. Additionally, the company is exploring IDE196 combinations with Pfizer and its potential in other rare skin diseases. In July 2022, IDEAYA signed an agreement with Amgen to evaluate IDE397 with Amgen's AMG 193 in solid tumors. Strategic pharma partnerships help advance and expand IDEAYA's pipeline of synthetic lethality precision oncology programs.
 
 
 
 
 Funding and financials
 
 
 
 
 
 The company was listed on the Nasdaq Global Select Market under the ticker symbol &ldquo;IDYA&rdquo; in May 2019, raising USD 50 million via an initial public offering. In September 2022, the company raised USD 92 million.&nbsp;
 
 
 
 
 For 2022, the company reported a net loss of USD 58.7 million (up 17.9% YoY) while collaboration revenue was USD 50.9 million (up 82.3% YoY). 
 
 
 On October 24, 2023, IDEAYA Biosciences priced an underwritten public offering of 5 million shares of common stock and pre-funded warrants to purchase 319,150 shares of common stock. The common stock offered was priced at USD 23.50 per share, while the exercise price of a pre-funded warrant was USD 0.0001. The offering was expected to bring in approximately USD 125 million in gross proceeds.
 
 
 
</div>

IDEAYA Biosciences

Companies providing genetic tests to identify individuals with high risk or at-risk of having hereditary disease, aid physicians with a diagnosis, and support clinical decision making.

Secure cloud-based platforms and data sharing networks that collect, index, store, and analyze large amounts of health data and patient population data sets from sources including genomic, clinical, wearables, imaging, and population data.

Biopharma and biotechnology companies that develop precision medicine drugs based on novel disease biomarkers present in multi-omic patient population data and genetic insights.

Companies that study intergenomic variations in genes associated with drug response and metabolism to match patients with the appropriate drug and dosage.

Companies that develop an in-vitro medical device or imaging tools and tests that identify genetic mutations for both diagnostic (nature of the disease) and prognostic (likely course of the disease) purposes, allowing providers to match a patient to a specific drug or therapy.

Software analytics platforms that integrate multiple omics datasets (genomics, transcriptomics, proteomics, and metabolomics) to gain insights and support target discovery, drug development, clinical trials, and diagnostics.

Some companies leverage AI/ML to develop tailored medication

Considers individual variability in genes, environment, and lifestyle for each person

Genomics is used across all the segments of precision medicine from diagnostic solutions to treatments

AI/ML analyzes genomic data to find drug targets, predict disease progression, and treatment response

PROMINENT_CATEGORY

<div>
 DNAnexus and Galatea Bio have formed a partnership to advance biomedical research and precision medicine, with a specific emphasis on improving data services for Latin American and other under-represented groups.
 In this agreement, Galatea Bio will use DNAnexus' cloud-based data services to help speed up and enhance the analysis of its varied non-European health data. This partnership will allow over 48,000 users from 48 diverse countries to potentially access Galatea's advanced genetic technologies. The collaboration is expected to improve the definition of ancestry-based polygenic risk scores, boost participant recruitment for clinical trials, and help Galatea Bio in extending its drug discovery strategies.
 Galatea Bio is a biotechnology business that aims to diversify genomic datasets by researching underrepresented populations, focusing on Latin America. The company offers clinical lab services designed to enhance health outcomes via genetic research. Galatea Bio also offers biobanking, especially through its Biobank of the Americas (BBofA) project. The project's goal is to gather and store genetic data from various populations and use the insights and data collected to design new pharmaceutical targets and algorithms.
 
</div>

DNAnexus

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless